Sathyan Iyer, MD
Family Medicine · Anniston, ALNPI 1801878368
Payments from drug & device makers
Across 357 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$484
- AstraZeneca$472
- Amgen$371
- Exact Sciences$371
- Pfizer$368
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,66798%
- Education$942%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 97 | $1,363 |
| GSK | 27 | $484 |
| AstraZeneca | 25 | $472 |
| Amgen | 22 | $371 |
| Exact Sciences | 24 | $371 |
| Pfizer | 23 | $368 |
| Lilly USA, LLC | 24 | $318 |
| Novo Nordisk | 19 | $246 |
| Abbott | 9 | $178 |
| Astellas Pharma US Inc | 5 | $170 |
| Axsome Therapeutics, Inc. | 6 | $152 |
| Boehringer Ingelheim | 9 | $146 |
| Bayer | 8 | $141 |
| Novartis | 6 | $122 |
| Merck | 7 | $98 |
| Xeris Pharmaceuticals, Inc. | 4 | $83 |
| Phathom Pharmaceuticals, Inc. | 4 | $79 |
| Teva Pharmaceuticals USA, Inc. | 5 | $76 |
| Dexcom, Inc. | 4 | $74 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $62 |
| Kowa Pharmaceuticals America, Inc. | 4 | $58 |
| Sanofi-aventis U.S. LLC | 3 | $50 |
| Eisai Inc. | 3 | $44 |
| Radius Health, Inc. | 3 | $44 |
| E.r. Squibb & Sons, L.L.C. | 3 | $37 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $29 |
| Johnson & Johnson | 2 | $29 |
| Biohaven Pharmaceuticals, Inc. | 2 | $28 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Triad Life Sciences Inc. | 1 | $21 |
| Almatica Pharma LLC | 1 | $17 |
How this compares
$5,761 in reported general payments places this provider in the 80th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 119 | $185,595 |
| EliquisApixaban | 207 | $170,503 |
| TrulicityDulaglutide | 101 | $145,700 |
| FarxigaDapagliflozin Propanediol | 164 | $140,445 |
| JanuviaSitagliptin Phosphate | 136 | $110,744 |
| JardianceEmpagliflozin | 70 | $105,060 |
| RybelsusSemaglutide | 52 | $101,694 |
| OzempicSemaglutide | 49 | $81,606 |
| Tresiba Flextouch U-100Insulin Degludec | 58 | $64,021 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $50,527 |
| XareltoRivaroxaban | 45 | $34,698 |
| Repatha SureclickEvolocumab | 30 | $29,397 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 58 | $26,073 |
| JanumetSitagliptin Phos/Metformin Hcl | 20 | $24,540 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 29 | $23,687 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $318 | $331,295220 claims |
| Novo NordiskRybelsus, Ozempic | $246 | $183,300101 claims |
| PfizerEliquis | $368 | $170,503207 claims |
| MerckJanuvia, Janumet, Janumet Xr | $98 | $158,971185 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $472 | $149,011178 claims |
| Boehringer IngelheimJardiance, Tradjenta | $146 | $118,81286 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta, Arexvy, Shingrix | $484 | $72,732126 claims |
| Johnson & JohnsonXarelto | $29 | $34,69845 claims |
| NovartisEntresto | $122 | $13,44813 claims |
| AbbVieLinzess | $1,363 | $7,38112 claims |
| Astellas Pharma US IncMyrbetriq | $170 | $6,65915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Anniston
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.